the NHLBI guidelines for SCA. 1 We recently showed that high circulating angiotensin-II (AT) in mice and humans with SCA increases mobilization of hematopoietic stem/progenitor cells. 2 Angiotensin-II (AT), signals through tissuebound AT receptors-1 (AT 1 R) and 22 (AT 2 R). While the detrimental role of increased AT signaling is known in non-SCA nephropathies, its role in SCA, and specifically SN, has not been studied.
We investigated whether high AT was secondary to increased renin in SCA. Renin catalyzes generation of AT from its precursor angiotensinogen (Supporting Information Figure S1a ). Hypoxia increases renin expression, thereby increasing AT production, which is the basis of reno-vascular hypertension. We postulated that in SCA, hypoxia from vaso-occlusions in vasa-recta could increase renin and consequently AT production. However, renin expression was not increased in kidneys of young sickle mice, despite high urinary AT levels (AT, a small octapeptide, readily filters through the glomerulus, and urine AT level reflects circulating and renal-generated AT) (Supporting Information Figure S1b-d) . Moreover, high AT was present in young children with SCA, in the absence of hypertension (Supporting Information Figure S1e -f). Hence, renin signaling does not appear to be the cause of high AT levels; its levels rise secondarily in older animals.
We next transplanted normal/wild-type mice (WT) mice with bone marrow from SS mice (SS!WT) to attain fully chimeric sickle mice (WT!WT chimeras were transplant controls). SS chimeras, but not WT chimeras, had hyperangiotensinemia (Supporting Information Fig- ure S1g), demonstrating that this effect was not secondary to transplant-induced vasculopathy. This data suggests that perhaps sickle hematopoiesis mediates hyperangiotensinemia, although the mechanism needs to be explored.
We investigated the role of high AT in SN. The features of SN seen in humans were closely mimicked in both SCA mouse models (Berkeley sickle [SS] mice and knock-in-SS mice, both exclusively carrying human sickle hemoglobin), including glomerular hyper-filtration, albuminuria, hyposthenuria, and progressively worsening FSGS. Indeed, the renal pathology in older SS mice was similar to that in a SCA patient with macro-albuminuria (Supporting Information Figure S2a -f).
These SCA mouse models were used for mechanistic studies.
We blocked AT signaling with captopril (ACE-I), or losartan (AT 1 R blocker) in SS mice. Both captopril and losartan abrogated albuminuria within 8-weeks, an effect sustained when treatment was continued for another 8-weeks ( Figure 1A ). This amelioration in glomerular defect was accompanied with improved renal histology (glomerulosclerosis, and mesangial proliferation) compared to the untreated SS controls Figure S4a -d), that were corrected by blocking ATsignaling with captopril/losartan ( Figure 1B) .
To confirm the pharmacological data, we transplanted sickle hematopoiesis into mice genetically deficient in AT 1 R, or AT 2 R, to create mice with SCA that lacked either AT 1 R (SS/AT 1 R-deficient) or AT 2 R (SS/AT 2 R-deficient), and compared them with sickle mice with intact AT 1 R 1 AT 2 R (SS/WT) ( Figure 1D ). Notably, only the SS/AT 1 R-deficient mice failed to develop sickle glomerulopathy: absent albuminuria and histopathological findings of FSGS and lack of increased TGFb1-Smad2/3 signaling ( Figure 1D , Supporting Information Figure S4e ,f).
We also generated knock-in-SS/AT 1 R deficient mice via interbreeding the knock-in-SS mice with AT 1 R-deficient mice. Knock-in-SS/AT 1 Rdeficient mice also had no albuminuria, unlike the knock-in mice with intact AT 1 R (Supporting Information Figure S5a ). AT 2 R signaling has been found to be glomerular-protective in other chronic renal injury disease models. 4 However, we found that AT signaling via AT 2 R did not cause sickle glomerulopathy since SS/AT 2 R- 
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deficient mice developed albuminuria and FSGS similar to SS/WT chimeras ( Figure 1D , Supporting Information Figure S4e ). Next, we augmented AT 2 R signaling with C21 (an AT 2 R agonist) in the context of AT 1 R blockade. SS mice that were administered C21 with losartan showed no improvement/worsening of albuminuria, as compared to losartan alone. Therefore, neither abrogation nor augmentation of AT 2 R signaling affected the sickle glomerulopathy ( Figure 1E ). Taken together, our pharmacological data and genetic models show that increased AT signaling promotes sickle glomerulopathy solely via AT 1 R.
Next, we analyzed how AT affected UCA. As expected, SS mice have significantly impaired UCA from sickling-mediated injury to vasa-recta and resultant loss of osmotic gradient. AT/AT 1 R signaling is known to increase sodium absorption from proximal tubules, and increase aquaporin expression, to concentrate urine. 5 Therefore, it was not surprising that the reduced UCA in SS mice (or SS/WT chimeras) worsened further with AT 1 R inhibition with losartan/captopril ( Figure   1F ,G). When SS mice (or SS/WT chimeras) were placed on captopril, however, we observed unusually high mortality from severe dehydration ( Figure 1H ). Urine osmolality (and urine albumin) in this treatment group could only be measured in the "fittest"/least dehydrated sickle mice when they were additionally given noncaptopril containing water supplementation. The significant increase in mortality from dehydration
with captopril (that reduces AT production, thus interrupting AT signaling via both receptors; Supporting Information Figure S1a ), but not with losartan (that only blocks AT 1 R signaling), suggests that AT may be improving UCA through AT 2 R as well. The anti-inflammatory and antifibrotic effects of AT 2 R activation have been proposed to be protective in glomerular injury; however its role in maintaining tubular function, specifically UCA, has not been explored. AT 2 R stimulation causes natriuresis and blood pressure regulation, and its deficiency is associated with severe experimentally-induced acute tubular necrosis. 4 We hypothesized that increased AT 2 R signaling probably compensates for loss of UCA with losartan, which may explain the captopril effect.
We therefore determined urine osmolality in SS/AT 1 R-deficient and SS/AT 2 R-deficient chimeric mice and compared them to SS/WT chimeras ( Figure 1I ). As expected, SS/WT mice had significantly lower urine osmolality than WT/WT mice. Both SS/AT 1 R-deficient and WT/ UCA was also reduced in knock-in-SS/AT 1 R deficient mice (Supporting Information Figure S5b ).
Urine osmolality in WT/WT versus WT/AT 2 R-deficient chimeras, however, was similar, suggesting that in healthy mice, AT 2 R plays no role in maintaining UCA. However, SS/AT 2 R-deficient mice had significantly lower urine osmolality than SS/WT chimeras demonstrating that AT 2 R is important in maintaining UCA in SCA, where it is likely recruited because the normal urine concentrating mechanisms are severely compromised ( Figure 1I ). Indeed, stimulation of AT 2 R signaling by giving SS mice C21, along with concomitant blockade of AT 1 R with losartan, improved their UCA to levels seen in control SS mice, showing that the effect of AT 1 R-deficiency on UCA could be compensated for, by increased AT 2 R signaling. (Figure 1J ). In a diabetic rat model, C21
treatment has been shown to be effective in reducing tubulointerstitial fibrosis. 4 Our data of improved UCA in SCA with C21 highlights another important reno-protective role of increased AT 2 R signaling.
Taken together, our data shows that in SCA, AT signaling via both AT 1 R and AT 2 R compensates for the sickling-mediated loss of UCA.
Notably, ACE-I have been evaluated for their effect on albuminuria in patients with SCA, although urine osmolality was not assessed in these trials. 6 It is conceivable that ACE-I may worsen UCA in SCA patients, which is either compensated for with increased water , PAS staining (603 magnification) and immunohistochemistry for phosphorylated Smad-2/3 (1003 magnification) in the kidneys of WT mice, untreated -SS control mice, or SS mice treated with captopril or losartan for 12 weeks. A single representative glomerulus is shown. Improvement in glomerular pathology including congestion, FSGS and mesangial proliferation is seen in SS mice on captopril or losartan compared to the untreated SS mice. Increased pSmad2/3 expression (brown staining) is seen in untreated SS compared to SS mice on captopril/losartan. (C) C57Bl/6 mice (WT; recipient) were transplanted with SS or WT donor bone marrow at 8-12 weeks of age following lethal irradiation (1275cGy) in a donor: recipient ratio of 1:7. Only SS/WT chimeras determined to be fully chimeric for SS by HPLC for hemoglobin S, 3 months after transplantation, were further analyzed for experiments. Untreated WT/WT chimeras (WT/WT-Ctrl; red bar), untreated SS chimeric mice (SS/WT-Ctrl; black bar), SS chimeric mice placed on captopril 3 months after transplant (SS/WT-Cap; blue bar) and SS chimeric mice placed on losartan 3 months after transplant (SS/WT-Los; green bar) were compared. Urine albumin and creatinine was analyzed 12 months after establishment of chimerism. UACR was determined on 24-hr urine samples by the urine albumin to creatinine ratio and data are expressed in mg albumin/mg creatinine is shown (n5 6-8 mice/group. (D) UACR levels in WT, AT 1 R -/and AT 2 R -/recipient mice transplanted with WT (red bars) or SS (black bars) donor bone marrow. Mice fully chimeric for WT or SS bone marrow at three months were analyzed. UACR was determined on 24-hr urine samples by the urine albumin to creatinine ratio and data are expressed in mg albumin/mg creatinine is shown (n 5 6-20 mice per group). (E) Urine albumin in SS mice (untreated or placed on only AT 1 R antagonist Losartan (Los) or placed on a combination of AT 2 R agonist C21, and Los; n 5 10-20 mice/group. (F) Temporal progression of UCA, measured by urine osmolality (Y-axis) in nontransplanted WT mice and SS mice (that were untreated, or treated with captopril or losartan) with weeks of drug treatment shown on the X-axis. Mice were started on drug treatment at 8-12 weeks of age. Urine osmolality could only be measured in captopril-treated mice if they were given additionally water without captopril, due to high mortality from severe dehydration. The urine osmolality data are expressed in mmol/kg and was measured in 24-hr urine collections (G) C57Bl/6 mice (WT; recipient) were transplanted with SS or WT donor bone marrow at 8-12 weeks of age following lethal irradiation (1275cGy) in a donor: recipient ratio of 1:7. Only SS/WT chimeras determined to be fully chimeric for SS by HPLC for hemoglobin S, 3 months after transplantation, were further analyzed for experiments. Untreated WT/WT chimeras (WT/WT-Ctrl; red bar), untreated SS chimeric mice (SS/WT-Ctrl; black bar), SS chimeric mice placed on captopril 3 months after transplant (SS/WT-Cap; blue bar) and SS chimeric mice placed on losartan 3 months after transplant (SS/WT-Los; green bar) were compared. Urine osmolality analyzed 12 months after establishment of donor chimerism. The urine osmolality data are expressed in mmol/kg and was measured in 24-hr urine (n 5 6-20 mice/group). 
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